Amgen Inc vs. Halozyme Therapeutics, Inc.
Amgen Inc (AMGN) comes out ahead, leading on 7 of 9 compared factors.
Size & Scale
| AMGN | HALO | |
|---|---|---|
| Market Cap | $205.32 billion | $12.45 billion |
| Revenue (TTM) | $38.09 billion | $1.66 billion |
| Net Income (TTM) | $8.74 billion | $413.60 million |
AMGN leads on 3 of 3 size & scale factors.
Valuation
| AMGN | HALO | |
|---|---|---|
| P/E Ratio | 23.95 | 32.63 |
| Price / Book | 17.57 | 86.72 |
| Price / Sales | 5.39 | 7.48 |
AMGN leads on 3 of 3 valuation factors.
Profitability
| AMGN | HALO | |
|---|---|---|
| Net Margin | 22.95% | 24.86% |
| Return on Equity | 74.80% | 288.13% |
HALO leads on 2 of 2 profitability factors.
Dividend
| AMGN | HALO | |
|---|---|---|
| Dividend Yield | 2.61% | — |
| Payout Ratio | 62.61 | — |
AMGN and HALO split the dividend factors evenly.
Risk & Sentiment
| AMGN | HALO | |
|---|---|---|
| Short Interest | 1.66% | 9.79% |
AMGN leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMGN overview, AMGN financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.